Corbus Pharmaceuticals Holdings Total Assets Growth & History (CRBP)
Corbus Pharmaceuticals Holdings's total assets was $168.2M for fiscal 2025.
View full Corbus Pharmaceuticals Holdings company overviewCorbus Pharmaceuticals Holdings annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $168.2M | $12.3M | +7.90% |
| 2024 | 2024-12-31 | $155.9M | $127.6M | +451.35% |
| 2023 | 2023-12-31 | $28.3M | −$38.0M | −57.37% |
| 2022 | 2022-12-31 | $66.3M | −$41.4M | −38.45% |
| 2021 | 2021-12-31 | $107.7M | $5.4M | +5.31% |
| 2020 | 2020-12-31 | $102.3M | $53.2M | +108.16% |
| 2019 | 2019-12-31 | $49.1M | $2.2M | +4.58% |
| 2018 | 2018-12-31 | $47.0M | −$20.0M | −29.84% |
| 2017 | 2017-12-31 | $67.0M | $49.1M | +274.43% |
| 2016 | 2016-12-31 | $17.9M | $5.0M | +38.93% |
| 2015 | 2015-12-31 | $12.9M | $6.3M | +95.06% |
| 2014 | 2014-12-31 | $6.6M | $6.3M | +2060.50% |
| 2013 | 2013-12-31 | $305,520 | — | — |
Corbus Pharmaceuticals Holdings quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $127.0M | $1.9M | +1.52% |
| Q1 2026 | 2026-03-31 | $144.5M | $4.5M | +3.25% |
| Q4 2025 | 2025-12-31 | $168.2M | $12.3M | +7.90% |
| Q3 2025 | 2025-09-30 | $109.5M | −$54.7M | −33.29% |
| Q2 2025 | 2025-06-30 | $125.1M | −$26.9M | −17.70% |
| Q1 2025 | 2025-03-31 | $139.9M | $14.2M | +11.28% |
| Q4 2024 | 2024-12-31 | $155.9M | $127.6M | +451.35% |
| Q3 2024 | 2024-09-30 | $164.2M | $127.9M | +352.47% |
| Q2 2024 | 2024-06-30 | $152.0M | $108.3M | +247.59% |
| Q1 2024 | 2024-03-31 | $125.7M | $74.1M | +143.48% |
| Q4 2023 | 2023-12-31 | $28.3M | −$38.0M | −57.37% |
| Q3 2023 | 2023-09-30 | $36.3M | −$37.5M | −50.86% |
| Q2 2023 | 2023-06-30 | $43.7M | −$38.3M | −46.72% |
| Q1 2023 | 2023-03-31 | $51.6M | −$44.0M | −46.02% |
| Q4 2022 | 2022-12-31 | $66.3M | −$41.4M | −38.45% |
| Q3 2022 | 2022-09-30 | $73.8M | −$45.7M | −38.26% |
| Q2 2022 | 2022-06-30 | $82.1M | −$38.5M | −31.96% |
| Q1 2022 | 2022-03-31 | $95.7M | −$44.5M | −31.73% |
| Q4 2021 | 2021-12-31 | $107.7M | $5.4M | +5.31% |
| Q3 2021 | 2021-09-30 | $119.6M | $23.7M | +24.77% |
| Q2 2021 | 2021-06-30 | $120.6M | $22.5M | +22.92% |
| Q1 2021 | 2021-03-31 | $140.1M | $74.9M | +114.93% |
| Q4 2020 | 2020-12-31 | $102.3M | $53.2M | +108.16% |
| Q3 2020 | 2020-09-30 | $95.8M | $27.7M | +40.67% |
| Q2 2020 | 2020-06-30 | $98.1M | $14.0M | +16.64% |
| Q1 2020 | 2020-03-31 | $65.2M | −$36.2M | −35.69% |
| Q4 2019 | 2019-12-31 | $49.1M | $2.2M | +4.58% |
| Q3 2019 | 2019-09-30 | $68.1M | $6.9M | +11.36% |
| Q2 2019 | 2019-06-30 | $84.1M | $13.8M | +19.68% |
| Q1 2019 | 2019-03-31 | $101.4M | $24.3M | +31.44% |
| Q4 2018 | 2018-12-31 | $47.0M | −$20.0M | −29.84% |
| Q3 2018 | 2018-09-30 | $61.2M | $22.8M | +59.25% |
| Q2 2018 | 2018-06-30 | $70.3M | $25.7M | +57.73% |
| Q1 2018 | 2018-03-31 | $77.1M | $26.5M | +52.43% |
| Q4 2017 | 2017-12-31 | $67.0M | $49.1M | +274.43% |
| Q3 2017 | 2017-09-30 | $38.4M | $18.7M | +94.46% |
| Q2 2017 | 2017-06-30 | $44.6M | $21.9M | +96.93% |
| Q1 2017 | 2017-03-31 | $50.6M | $40.1M | +382.19% |
| Q4 2016 | 2016-12-31 | $17.9M | $5.0M | +38.93% |
| Q3 2016 | 2016-09-30 | $19.8M | $6.4M | +48.17% |
| Q2 2016 | 2016-06-30 | $22.6M | $13.1M | +136.57% |
| Q1 2016 | 2016-03-31 | $10.5M | $5.2M | +100.05% |
| Q4 2015 | 2015-12-31 | $12.9M | $6.3M | +95.06% |
| Q3 2015 | 2015-09-30 | $13.3M | $5.7M | +74.77% |
| Q2 2015 | 2015-06-30 | $9.6M | — | — |
| Q1 2015 | 2015-03-31 | $5.2M | — | — |
| Q4 2014 | 2014-12-31 | $6.6M | $6.3M | +2060.50% |
| Q3 2014 | 2014-09-30 | $7.6M | — | — |
| Q4 2013 | 2013-12-31 | $305,520 | — | — |
Corbus Pharmaceuticals Holdings total assets trends
Over the last five fiscal years, Corbus Pharmaceuticals Holdings's total assets increased from $102.3M to $168.2M, a change of $65.9M. The latest reported quarter, Q2 2026, shows $127.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corbus Pharmaceuticals Holdings source filings ↗